EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

APJ as Promising Therapeutic Target of Peptide Analogues in Myocardial Infarction- and Hypertension-Induced Heart Failure

Daniela Rossin iD, Roberto Vanni, Marco Lo Iacono iD, Caterina Cristallini iD, Claudia Giachino iD, Raffaella Rastaldo iD

Pharmaceutics · 04.05.2023 · 15 (5) · 1408

DOI: 10.3390/pharmaceutics15051408 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 04.05.2023. Verfasst von Daniela Rossin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Universities and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The widely expressed G protein-coupled apelin receptor (APJ) is activated by two bioactive endogenous peptides, apelin and ELABELA (ELA). The apelin/ELA-APJ-related pathway has been found involved in the regulation of many physiological and pathological cardiovascular processes. Increasing studies are deepening the role of the APJ pathway in limiting hypertension and myocardial ischaemia, thus reducing cardiac fibrosis and adverse tissue remodelling, outlining APJ regulation as a potential therapeutic target for heart failure prevention. However, the low plasma half-life of native apelin and ELABELA isoforms lowered their potential for pharmacological applications. In recent years, many research groups focused their attention on studying how APJ ligand modifications could affect receptor structure and dynamics as well as its downstream signalling. This review summarises the novel insights regarding the role of APJ-related pathways in myocardial infarction and hypertension. Furthermore, recent progress in designing synthetic compounds or analogues of APJ ligands able to fully activate the apelinergic pathway is reported. Determining how to exogenously regulate the APJ activation could help to outline a promising therapy for cardiac diseases.

Schlagwörter

Stichwörter der Autor:innen

APLNR/APJ receptorELABELA/Toddler/Apelaangiogenesisapelincardiovascular diseasefibrosisheart failurehypertensionmyocardial infarctionpeptide analogue

Autor:innen und Institutionen

  • Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.
  • Institute for Chemical and Physical Processes, IPCF ss Pisa, CNR, 56126 Pisa, Italy.

ORCID-Profile: Daniela Rossin, Marco Lo Iacono, Caterina Cristallini, Claudia Giachino, Raffaella Rastaldo

Förderung

  • Ministry of Education, Universities and Research

Zitieren

APA

Rossin, D., Vanni, R., Lo Iacono, M., Cristallini, C., Giachino, C., & Rastaldo, R. (2023). APJ as Promising Therapeutic Target of Peptide Analogues in Myocardial Infarction- and Hypertension-Induced Heart Failure. Pharmaceutics, 15(5), 1408. https://doi.org/10.3390/pharmaceutics15051408

Vancouver

Rossin D, Vanni R, Lo Iacono M, Cristallini C, Giachino C, Rastaldo R. APJ as Promising Therapeutic Target of Peptide Analogues in Myocardial Infarction- and Hypertension-Induced Heart Failure. Pharmaceutics. 2023;15(5):1408. doi:10.3390/pharmaceutics15051408

BibTeX
@article{Rossin2023,
  author = {Rossin, Daniela and Vanni, Roberto and Lo Iacono, Marco and Cristallini, Caterina and Giachino, Claudia and Rastaldo, Raffaella},
  title = {APJ as Promising Therapeutic Target of Peptide Analogues in Myocardial Infarction- and Hypertension-Induced Heart Failure},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {5},
  pages = {1408},
  doi = {10.3390/pharmaceutics15051408}
}
Kostenlos starten →